Cybin announces publication in frontiers in psychology journal introducing embark, an integrative model of psychedelic therapy

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a biopharmaceutical company focused on progressing “psychedelics to therapeutics™”, is pleased to announce the publication of a peer-reviewed article introducing embark, a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. “it's a pleasure to see our work published in this respec
CYBN Ratings Summary
CYBN Quant Ranking